Finch Therapeutics Group Inc
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
(0.0% 1d) (-9.7% 1m) (-78.1% 1y) (0.0% 2d) (-18.7% 3d) (24.1% 7d) (-81.77% volume)
Earnings Calendar: 2023-03-30
Market Cap: $ 3,853,831
https://finchtherapeutics.com
Sec Filling | Patents | n/a employees
Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs. With the capabilities to develop both complete and targeted microbiome therapeutics, Finch is advancing a rich pipeline of candidates designed to address a wide range of unmet medical needs. Finch’s lead candidate, CP101, is in late-stage clinical development for the prevention of recurrent C. difficile infection (CDI), and has received Breakthrough Therapy and Fast Track designations from the U.S. Food and Drug Administration. In June 2020, Finch announced that CP101 met its primary efficacy endpoint in PRISM3, the first of two pivotal trials to support the development of CP101 for the prevention of recurrent CDI. Finch plans to initiate a Phase 3 trial, referred to as PRISM4, as its second pivotal trial of CP101 for recurrent CDI. Finch is also developing CP101 for the treatment of chronic hepatitis B virus, and FIN-211 for the treatment of the gastrointestinal and behavioral symptoms of autism spectrum disorder. In partnership with Takeda, Finch is advancing FIN-524 and FIN-525 for the treatment of ulcerative colitis and Crohn’s disease, respectively.
hepatitis gastrointestinal treatment injection
add to watch list Paper trade email alert is off
Press-releases
Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth, Technavio
Published: 2024-03-06 (Crawled : 15:30) - prnewswire.com
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: 4.12%
H: 0.97%
C: 0.97%
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -4.0%
H: 4.92%
C: 4.12%
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: 4.24%
H: 0.0%
C: -7.14%
PHGE | News | $0.2937 4.86% 0.1% 110K
|
Health Technology
|
| O: 211.55%
H: 18.75%
C: -4.46%
america million therapeutics market
Human Microbiome Therapeutics Market size to grow by USD 732.95 million from 2022 to 2027, North America to account for 41% of market growth - Technavio
Published: 2024-01-08 (Crawled : 10:00) - prnewswire.com
PTCHF | $2.78 19.97% 560
|
n/a
|
| O: 3.67%
H: 0.19%
C: 0.19%
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: 6.09%
H: 3.01%
C: -4.37%
EVGN | $0.7 -13.64% 63K
|
Health Technology
|
| O: -6.76%
H: 3.38%
C: 0.3%
PHGE | News | $0.2937 4.86% 0.1% 110K
|
Health Technology
|
| O: 0.04%
H: 0.0%
C: -3.15%
america million therapeutics growth market
Finch Announces Reverse Stock Split of Common Stock
Published: 2023-06-09 (Crawled : 11:00) - globenewswire.com
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -5.26%
H: 5.52%
C: 0.37%
Finch Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Updates
Published: 2023-05-10 (Crawled : 11:00) - globenewswire.com
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -6.31%
H: 4.68%
C: 0.38%
HTGC F | $18.25 0.5% 0.0% 590K
|
Finance
|
| O: 1.13%
H: 1.93%
C: 0.97%
business therapeutics financial results
Global Microbiome Therapeutics Markets Report, 2021-2022 & 2023-2027 Featuring Major Players Assembly Biosciences, Finch Therapeutics, Second Genome, Evelo Biosciences and Ysopia Bioscience
Published: 2023-04-24 (Crawled : 19:00) - prnewswire.com
TOVX | $0.4475 2.87% 0.11% 29K
|
Manufacturing
|
| O: 0.0%
H: 4.4%
C: 2.16%
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -9.12%
H: 6.62%
C: -0.9%
bioscience global therapeutics
Finch Therapeutics Announces Clinical Collaboration in Ulcerative Colitis with Brigham and Women’s Hospital and Updates to University of Minnesota License Agreement
Published: 2023-04-18 (Crawled : 00:00) - biospace.com/
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -5.18%
H: 7.24%
C: 7.14%
license hospital collaboration therapeutics agreement
Global Microbiome Therapeutics Market Analysis Report 2023: A $1.46 Billion Market by 2027 Featuring Major Players - Assembly Bio, Finch Therapeutics, Second Genome, Evelo Bio, Ysopia Bio
Published: 2023-02-10 (Crawled : 04:00) - prnewswire.com
TOVX | $0.4475 2.87% 0.11% 29K
|
Manufacturing
|
| O: 2.57%
H: 0.0%
C: -6.31%
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -3.01%
H: 4.34%
C: 3.31%
global report therapeutics market
Finch Therapeutics Announces Decision to Discontinue Phase 3 Trial of CP101 and Focus on Realizing the Value of Its Intellectual Property Estate and Other Assets
Published: 2023-01-24 (Crawled : 15:00) - biospace.com/
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: 11.64%
H: 8.91%
C: -11.63%
cp101 trial therapeutics
Finch Therapeutics Presents PRISM-EXT Biomarker Data at ACG 2022 and Proceeds with Patient Dosing in Phase 3 Trial of CP101 in Recurrent C. Difficile Infection
Published: 2022-10-24 (Crawled : 19:00) - biospace.com/
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: 3.7%
H: 12.86%
C: 10.0%
cp101 biomarker trial therapeutics infection
Finch Therapeutics Regains Full Rights to FIN-524 and FIN-525 Targeted Microbiome Product Candidates in Development for IBD
Published: 2022-08-25 (Crawled : 21:00) - globenewswire.com
FNCH | $2.4 -4.76% -5.0% 26K
|
Professional, Scientific, and T...
|
| O: -8.01%
H: 4.86%
C: 2.43%
TAK | News | $13.16 0.08% 0.0% 1.3M
|
Health Technology
|
| O: -0.78%
H: 0.65%
C: -1.44%
fin-524 therapeutics
Last 15 days Sec forms
| File Id | Form | Published Date | Transaction Date | Direction | Code | Amount Transacted | Owned Amount |
| 0000950170-23-066155 | 4 | 2023-11-27 | 2023-11-22 | Sell | S | 1470 | 6642 |
Your Today's Watch List
Sign in to create a watchlistGainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | News | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | News | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | News | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | News | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Last 48 Hours Insiders Buying
AXR P 2400 | $22.17 2.69% 0.0% 5.5K
|
Finance
|
21:00
QCRH P 118 | $55.405 1.33% 1.31% 54K
|
Finance
|
18:01
VUZI P 7500 | $1.26 3.28% 3.17% 1M
|
Electronic Technology
|
18:00
RMCF | $3.61 2.27% 2.22% 18K
|
Consumer Non-Durables
|
20:10